Call Us: 888-488-5750

VativoRx cited as a Top 10 PBM solutions provider

In the current issue of My Tech Mag, Pharmacy Management edition, VativoRx is called out as being one of the ten best pharmacy management solutions providers in the United States.

Our Director of Operations, Rosalyn Banks, talked about the work ethic that got VativoRx onto that list.

“At VativoRx we don’t focus on competitors. We stick to our core beliefs, mission statement and remain innovative. The industry has several outdated concepts we push the envelope on to provide the best quality services and products to the companies we partner with,” says Rosalyn.

“VRX Connect, our proprietary software, gives us an edge in the market and has allowed us to identify a niche, providing services our competitors are not.” 

To read the full article, click here.

Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »

Biosimilars — Similar But Not Identical

You may have never heard of biosimilar drugs and that’s probably because they are not commonly prescribed in the United States even though they have been around for over 20 years. So, what are biosimilar drugs? A biosimilar drug is no different in terms of safety and effectiveness than a biologic product, also known as a reference product, and while highly similar it is not identical.

Read More »

Lower Cost Prescription Drugs from Canada, Is It Legal?

In the early 2000s, the FDA set up guidelines in the Regulatory Procedures Manual (RPM) that permitted prescription drugs to be imported from other countries if the patient met very strict guidelines. Just stating that the patient needed the drug due to cost savings was not a justification to obtain the drug.

Read More »